Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease.  The open public hearing portion of the meeting will be conducted virtually. The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of ...